181 related articles for article (PubMed ID: 2449025)
1. Therapy with interferons in blood diseases.
Polli E; Cortelezzi A
Acta Haematol; 1987; 78 Suppl 1():64-9. PubMed ID: 2449025
[TBL] [Abstract][Full Text] [Related]
2. [Interferons in the treatment of hematological diseases].
Jantunen E; Nousiainen T
Duodecim; 1998; 114(12):1240-7. PubMed ID: 11524770
[No Abstract] [Full Text] [Related]
3. Interferons for malignant blood diseases?
Hokland M; Hokland P
Eur J Haematol; 1987 Mar; 38(3):209-12. PubMed ID: 2439370
[No Abstract] [Full Text] [Related]
4. Interferons and interferon inducers in cancer treatment.
Krown SE
Semin Oncol; 1986 Jun; 13(2):207-17. PubMed ID: 2424089
[No Abstract] [Full Text] [Related]
5. [Quantitative immunoglobulin determination as a monitoring technic in hematologic diseases under cytostatic therapy].
Knolle J; Wörz R; Meyer zum Büschenfelde
Verh Dtsch Ges Inn Med; 1969; 75():492-7. PubMed ID: 4099583
[No Abstract] [Full Text] [Related]
6. The clinical value of interferons as antitumor agents.
Billiau A
Eur J Cancer Clin Oncol; 1981 Sep; 17(9):949-67. PubMed ID: 6173223
[No Abstract] [Full Text] [Related]
7. [Interferon therapy in hematologic neoplasms].
Schwarzinger I; Bettelheim P; Lechner K
Wien Klin Wochenschr; 1988 Aug; 100(15):497-504. PubMed ID: 2459854
[TBL] [Abstract][Full Text] [Related]
8. Interferon therapy for lymphoproliferative disorders.
Roth MS; Bunn PA; Foon KA
Cancer Treat Res; 1988; 38():231-52. PubMed ID: 2484433
[No Abstract] [Full Text] [Related]
9. Interferon treatment of human neoplasia.
Strander H
Adv Cancer Res; 1986; 46():1-265. PubMed ID: 2425561
[No Abstract] [Full Text] [Related]
10. Repeated transfusions of autologous cytokine-induced killer cells for treatment of haematological malignancies in elderly patients: a pilot clinical trial.
Yang B; Lu XC; Yu RL; Chi XH; Liu Y; Wang Y; Dai HR; Zhu HL; Cai LL; Han WD
Hematol Oncol; 2012 Sep; 30(3):115-22. PubMed ID: 22972689
[TBL] [Abstract][Full Text] [Related]
11. [Interferon: facts and hopes. I. Properties of interferon].
Dmoszyńska-Giannopoulou A; Rupniewska ZM
Pol Arch Med Wewn; 1981 Oct; 66(4):303-6. PubMed ID: 6174953
[No Abstract] [Full Text] [Related]
12. Biotherapy with interferon in hematologic malignancies.
Roth MS; Foon KA
Oncol Nurs Forum; 1987; 14(6 Suppl):16-22. PubMed ID: 2447569
[No Abstract] [Full Text] [Related]
13. Interferon therapy in cancer: from imaginon to interferon.
Goldstein D; Laszlo J
Cancer Res; 1986 Sep; 46(9):4315-29. PubMed ID: 2425950
[No Abstract] [Full Text] [Related]
14. Studies on antiviral and antitumor effects of human leukocyte interferon in vitro and in vivo.
Strander H; Cantell K
In Vitro Monogr; 1974; (3):49-56. PubMed ID: 4471024
[No Abstract] [Full Text] [Related]
15. Interferons: several questions and few answers.
Stewart WE
Adv Exp Med Biol; 1983; 166():15-21. PubMed ID: 6196954
[TBL] [Abstract][Full Text] [Related]
16. Cytokines in the treatment of hematological disorders: recent progress and perspectives.
Robak T
Arch Immunol Ther Exp (Warsz); 1996; 44(1):5-9. PubMed ID: 8874763
[TBL] [Abstract][Full Text] [Related]
17. [In vitro study of the effect of human leukocyte interferon on cell division and natural killer cell activity].
Görög G; Onody K; Tóth M; Benczúr M; Petrányi G; Béládi I; Hollán Z
Orv Hetil; 1982 Jun; 123(24):1479-82. PubMed ID: 6180377
[No Abstract] [Full Text] [Related]
18. Interferon: a perspective.
Weissman RM; Droller MJ
Invest Urol; 1980 Nov; 18(3):189-96. PubMed ID: 6159334
[No Abstract] [Full Text] [Related]
19. Lenalidomide: a synthetic compound with an evolving role in cancer management.
Saloura V; Grivas PD
Hematology; 2010 Oct; 15(5):318-31. PubMed ID: 20863427
[TBL] [Abstract][Full Text] [Related]
20. The role of recombinant hematopoietic growth factors in blood diseases.
Jimenez JJ; Vargas-Cuba R; Temple JD
Adv Intern Med; 1990; 35():393-414. PubMed ID: 2405600
[No Abstract] [Full Text] [Related]
[Next] [New Search]
